Company Profile
Pasithea Therapeutics Stock Price, News & Analysis
- Ticker:
- KTTA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.44 USD (-1.42%)
Close
Last updated: August 6, 2026
21.6M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, KTTA closed down 1.42% at $0.4436. No new same-company headline was identified in the current news window.
Company overview
Business overview
Pasithea Therapeutics is a biotechnology company focused on neuropsychiatric disorders and inflammation-linked biology. Its story centers on developing treatments for difficult CNS conditions with limited effective options.
Geographic Base and Sector Classification
Pasithea is headquartered in the United States and listed on NASDAQ. It sits in small-cap biotechnology with a neuroscience angle.
Business Model Characteristics
The company depends on clinical progress, translational validation, and capital efficiency. Investors generally watch early data, program resets, and whether the company can maintain a coherent development strategy.
Position Within the Biotechnology Landscape
Pasithea occupies a speculative neuroscience niche within biotech. The stock tends to be driven by the market's willingness to underwrite a narrow CNS thesis.
Future catalysts
Pasithea’s catalysts are oncology and CNS programs, along with any strategic step that clarifies what the company is really building. The stock remains highly dependent on a cleaner path.
Recent news
- 01
- 02
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Source: Pasithea Therapeutics
- 03
- 04
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
Source: Pasithea Therapeutics
- 05
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
Source: Pasithea Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Pasithea Therapeutics (KTTA)?
Pasithea Therapeutics (KTTA) most recently closed at 0.44 USD, a -1.42% move versus the previous session.
What is the market cap of Pasithea Therapeutics (KTTA)?
Pasithea Therapeutics currently has a market capitalization of 21.6M USD on BioPharmSignal.
What does Pasithea Therapeutics do?
Pasithea Therapeutics is a biotechnology company focused on neuropsychiatric disorders and inflammation-linked biology. Its story centers on developing treatments for difficult CNS conditions with limited effective options.
On which exchange is KTTA stock listed?
Pasithea Therapeutics (KTTA) is associated with NASDAQ, United States, Biopharma.
What is Pasithea?
Pasithea’s catalysts are oncology and CNS programs, along with any strategic step that clarifies what the company is really building.
Which conditions is Pasithea Therapeutics targeting with Pasithea?
Pasithea Therapeutics is associated with oncology, inflammatory disease based on its company overview and current catalyst commentary.
How does Pasithea Therapeutics describe recent progress with Pasithea?
Pasithea’s catalysts are oncology and CNS programs, along with any strategic step that clarifies what the company is really building.
What is Therapeutics?
Pasithea Therapeutics is a biotechnology company focused on neuropsychiatric disorders and inflammation-linked biology.